Skip to content

Electrolyte and Fluid Disturbances in Subarachnoid Hemorrhage and Traumatic Brain Injury

Disturbances of the Sodium and Fluid Balance in Patients With Severe Traumatic Brain Injury and Non-traumatic Subarachnoid Hemorrhage. A Systematic Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01313975
Enrollment
85
Registered
2011-03-14
Start date
2011-01-31
Completion date
2013-01-31
Last updated
2013-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Electrolyte Disturbances, Natriuretic Peptides, Subarachnoid Hemorrhage, Traumatic Brain Injury

Keywords

Electrolyte disturbances, Fluid balance, subarachnoid hemorrhage, traumatic brain injury, Cerebral salt wasting, SIADH, Diabetes insipidus

Brief summary

During the course of their acute illness patients with subarachnoid hemorrhage and severe traumatic brain injury often develop disturbances in their fluid balance and electrolyte homeostasis. These shifts are associated with worse outcome and increased morbidity. The aim of this observational study is to systematically analyze the incidence, characteristics, potential diagnostic markers and predisposing factors of such disturbances. The investigators hypothesize that many disturbances cannot be classified with a standard diagnostic approach and that variable fluid management contributes to their pathophysiology. Patients will be closely monitored clinically and the exact fluid and electrolyte balances will be recorded. Treatment decisions are within the bedside physicians responsibility. Baseline fluid management is standardised. No interventions are planned. The observation period equal the duration of ICU stay.

Detailed description

Background Electrolyte disturbances and fluid shifts are common in patients with subarachnoid hemorrhage (SAH) or traumatic brain injury (TBI). They usually have a rapid onset with impact on morbidity (possibly mortality) and length of stay. So far the understanding of underlying pathophysiologies and the contribution of iatrogenic influences is not fully understood. Only limited evidence and data on classification, management and outcome of patients exists. Objective To describe the incidence, characteristics and duration of sodium and fluid disturbances in patients with SAH or TBI. To document exact fluid and electrolyte management To evaluate predisposing factors and potential predicting biomarkers such as natriuretic peptides, renin-aldosterone system. Methods Prospective systematic observational study with 50 patients in the SAH group and 50 patients in the TBI group. 8hourly clinical assessment, blood and urin samples. Defined trigger points for additional measurements. Continuous fluid balance documentation Daily measurement of natriuretic peptides, aldosterone and renin

Interventions

None listed

Sponsors

Foundation for research in Anaesthesie and Intensive Care Medicine
CollaboratorUNKNOWN
Brahms AG
CollaboratorINDUSTRY
Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* non-traumatic subarachnoid hemorrhage * severe traumatic brain injury (GCS\<9)

Exclusion criteria

* younger than 18 years * time to admission after injury or bleed more than 7days * death expected in less than 12hours

Design outcomes

Primary

MeasureTime frame
Incidence of sodium-fluid disturbances14 days

Secondary

MeasureTime frameDescription
Type of sodium abnormality14 days
Haemodynamic changes, 8hourly urine output, 8hourly fluid and sodium balance, changes in fluid management by treating doctors associated with sodium disturbances14 daysWe measure all parameters for multivariate analysis to find common predictors for sodium and fluid balance disturbances in these patients
Associated changes in natriuretic peptide levels14 days

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026